Polyrizon Ltd. (PLRZ)
Polyrizon Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ra'anana, TA, IL. The stock last traded at $10.80, up 5.99% on the session, giving a market capitalisation of $12.1M. On trailing twelve-month figures it carries a trailing P/E of -3.09, a net margin of 0.0%. Its beta of -1.46 implies it has historically moved less than the broad market.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Polyrizon Ltd. is most often compared with the following Healthcare names: